In July 2018, the Canadian Agency for Drugs and Technologies in Health (CADTH) recommended not to reimburse dupilumab.
This is in contrast to the support and positive opinions conveyed by the fact that dupilumab (co-developed by Regeneron Pharmaceuticals and Sanofi) was approved in four major global regions (the US, the EU, Canada, and Japan) within a ten-month period beginning March 2017, and followed swiftly by a positive Final Appraisal Determination (FAD) published by the National Institute for Health and Care Excellence (NICE) in June 2018. 
In late 2017, hope was sparked for patients and clinicians when Health Canada approved the agent for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. 
This negative decision from the CADTH has raised fears that patient access to this clinically-proven, effective treatment will be severely limited, especially for those relying on public drug plans and the ability for physicians to be freely available to prescribe this medication. 
Image credit: Gemma Evans Unsplash